Skip to content

Cancers & treatments

News & evidence

Living with cancer

Learn & contribute

Loading

A public, cited, editable map of oncology: technologies, targets, products, companies, institutions, pathways, trials, pairings, roadmaps, and ideas. One page per object, with a plain-language TL;DR on every page.

Work in progress. Every fact on this site is being built and checked in the open and may be incomplete, out of date, or wrong. You must do your own research and verify anything here at its primary source before relying on it. Nothing on this site is medical advice; decisions belong with you and your clinicians.

OnCo is an information resource, not medical advice. Nothing here replaces a conversation with a qualified clinician. Never delay care because of something you read here; in an emergency, call your local emergency services. Terms of use

Browse by cancer
Tags
Search
Connections
For me
Navigator
Biomarker matrix
Calculators
Interactions
Decision aids
Checkpoint side effects
Tumour board
Compare
Counts by category
Rankings
Timeline
Year by year
Query builder
Graph explorer
Saved
Body map

Cancers & treatments

News & evidence

Institutions & people

Institutions
Universities
Trial leadership
People
Heroes and heroines
Companies
Startups
Requests for startups
Investors
Company scorecards
Trial sponsors
Manufacturing map
Countries
United States deep dive
India deep dive
China deep dive
Germany deep dive
Israel deep dive
United Kingdom deep dive
Cases by country
Funding flows

Living with cancer

For me
The first 60 days
Appointment prep pack
Side effects
Symptom to test
Report reader
Survivorship planner
Second opinion
Financial help
Free in oncology
Paying for care in the US
NHS coverage
Paying for care in India
Coverage rankings
Cutting cancer care costs
Diet, exercise and lifestyle
Supportive care
Recovery and rejuvenation
Complementary and supportive approaches
Hair loss and regrowth
What comes back after treatment
Heroes and heroines

Learn & contribute

Reading paths
About & methodology
Roadmap
Gaps to fill
Coverage of the field
Review queue
Reviewer roster
Contributors
Idea votes
Teaching packs
Weekly issue
Suggest an edit
Answer quality
Data dictionary
Build on OnCo
Open API
Open data
Open tools
Open source in oncology
The software of oncology
GitHub

© 2026 OnCo. Code MIT. The data are free for individual and educational use with the attribution “Data from OnCo (onco.cc)”, under CC BY-NC 4.0. Commercial use must contact us to pay for the data. Commercial licences. Made with heart and soul by Jude Gomila .

About and methodology Corrections Open API Tags Terms of use Privacy policy GitHub

Loading

Home
Cancers
Relapsed or refractory multiple myeloma
What changed

Relapsed or refractory multiple myeloma

What changed: Relapsed or refractory multiple myeloma

Cancer page →

Every dated change on the records linked to Relapsed or refractory multiple myeloma, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.

Overview Types and stages Symptoms and diagnosis Treatment Trials and papers Biology and targets Countries and centres Decisions and support Pipeline and open problems Data

Approval6Regulatory1Trial result11Milestone7This record1On Edge

FollowWatch this cancer and Saved shows what changed since you last looked.Follow by feed

September 2026 · 1

2026-09-17This recordRelapsed or refractory multiple myeloma
Facts on this page last checked
When this page itself was last checked or edited.

2025 · 3

2025Trial resultiMMagine-1
iMMagine-1 reported
ORR 97%.
2025Trial resultMajesTEC-3
MajesTEC-3 reported
36-month PFS 83.
2025MilestoneLinvoseltamab
Linvoseltamab approved; belantamab returns after DREAMM-7 and DREAMM-8; MajesTEC-3 reads out
A milestone in how this cancer is treated.

April 2024 · 1

2024-04-05RegulatoryCiltacabtagene autoleucel
Ciltacabtagene autoleucel: approval (US)
Relapsed myeloma after ≥1 prior line, lenalidomide-refractory (CARTITUDE-4)

2024 · 4

2024ApprovalCiltacabtagene autoleucel
Ciltacabtagene autoleucel approved in US
Relapsed myeloma after ≥1 line, lenalidomide-refractory
2024Trial resultDREAMM-7
DREAMM-7 reported
PFS 36.
2024Trial resultDREAMM-8
DREAMM-8 reported
PFS HR 0.
2024Trial resultLINKER-MM1
LINKER-MM1 reported
ORR 70%, ≥CR 45%.

2023 · 4

2023Trial resultCARTITUDE-4
CARTITUDE-4 reported
PFS HR 0.
2023Trial resultKarMMa-3
KarMMa-3 reported
PFS 13.
2023Trial resultMagnetisMM-3
MagnetisMM-3 reported
ORR 61%.
2023MilestoneKarMMa-3
KarMMa-3 and CARTITUDE-4: CAR-T beats standard regimens in randomised trials; talquetamab and elranatamab approved
A milestone in how this cancer is treated.

2022 · 3

2022Trial resultMajesTEC-1
MajesTEC-1 reported
ORR 63%, ≥CR 39%.
2022Trial resultMonumenTAL-1
MonumenTAL-1 reported
ORR ~73%.
2022MilestoneTeclistamab
Teclistamab: first BCMA bispecific approved (MajesTEC-1)
A milestone in how this cancer is treated.

2021 · 2

2021Trial resultCARTITUDE-1
CARTITUDE-1 reported
ORR 98%; ~33% progression-free at 5 years without maintenance.
2021MilestoneIdecabtagene vicleucel
Ide-cel: first BCMA CAR-T approved
A milestone in how this cancer is treated.

2020 · 2

2020ApprovalBelantamab mafodotin
Belantamab mafodotin approved in US
Relapsed myeloma ≥4 lines (accelerated; withdrawn 2022)
2020ApprovalIsatuximab
Isatuximab approved in US
Relapsed myeloma with pomalidomide-dexamethasone; 2021 with carfilzomib-dexamethasone

2015 · 2

2015ApprovalDaratumumab
Daratumumab approved in US
Relapsed myeloma after ≥3 lines
2015MilestoneDaratumumab
Daratumumab, the first CD38 antibody, approved for heavily pretreated myeloma
A milestone in how this cancer is treated.

2012 · 2

2012ApprovalCarfilzomib
Carfilzomib approved in US
Relapsed myeloma (accelerated)
2012MilestoneCarfilzomib
Carfilzomib approved; pomalidomide follows in 2013
A milestone in how this cancer is treated.

2003 · 2

2003ApprovalBortezomib
Bortezomib approved in US
Relapsed myeloma (accelerated)
2003MilestoneBortezomib
Bortezomib approved for relapsed myeloma: the first proteasome inhibitor
A milestone in how this cancer is treated.